Cargando…

Abnormal amyloid β(42) expression and increased oxidative stress in plasma of CKD patients with cognitive dysfunction: A small scale case control study comparison with Alzheimer's disease

BACKGROUND: Cognitive dysfunction has been increasingly recognized in chronic kidney disease (CKD) patients. Senile plaques are important pathophysiological characteristic of cognitive dysfunction. The major component of plaques is the amyloid β (Aβ) peptide released from proteolytic cleavage of amy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vinothkumar, G., Kedharnath, C., Krishnakumar, S., Sreedhar, S., Preethikrishnan, K., Dinesh, S., Sundaram, A., Balakrishnan, D., Shivashekar, G., Sureshkumar, Venkataraman, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491400/ https://www.ncbi.nlm.nih.gov/pubmed/28702365 http://dx.doi.org/10.1016/j.bbacli.2017.06.001

Ejemplares similares

Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia
por: Ying, Chunwei, et al.
Publicado: (2023)

Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease
por: Kerbler, Georg M, et al.
Publicado: (2014)

Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease
por: Iaccarino, Leonardo, et al.
Publicado: (2017)

Mutation-based structural modification and dynamics study of amyloid beta peptide (1–42): An in-silico-based analysis to cognize the mechanism of aggregation
por: Panda, Pritam Kumar, et al.
Publicado: (2016)

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
por: Oh, Esther S., et al.
Publicado: (2018)

Systems modeling of white matter microstructural abnormalities in Alzheimer's disease
por: Horgusluoglu-Moloch, Emrin, et al.
Publicado: (2020)

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
por: Withington, Charles G., et al.
Publicado: (2022)

Beta-amyloid and Cortical Thickness Reveal Racial Disparities in Preclinical Alzheimer's Disease
por: McDonough, Ian M.
Publicado: (2017)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)
por: Chincarini, A., et al.
Publicado: (2019)

Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
por: Fertan, Emre, et al.
Publicado: (2023)

Regional staging of white matter signal abnormalities in aging and Alzheimer's disease
por: Lindemer, Emily R., et al.
Publicado: (2017)

CKD-MBD diagnosis: biochemical abnormalities
por: Lucca, Leandro Junior, et al.
Publicado: (2021)

Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy
por: Putcha, Deepti, et al.
Publicado: (2019)

Lower Cerebrospinal Fluid Amyloid-β(42) Predicts Sooner Time to Antipsychotic Use in Alzheimer’s Disease
por: Cahan, Joshua G., et al.
Publicado: (2023)

Compulsive-like Behaviors in Amyloid-β 1-42–Induced Alzheimer’s Disease in Mice Are Associated With Hippocampo-cortical Neural Circuit Dysfunction
por: Shivakumar, Apoorva Bettagere, et al.
Publicado: (2023)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
por: Kollhoff, Alexander L., et al.
Publicado: (2018)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Oligomer Formation by Amyloid-β42 in a Membrane-Mimicking Environment in Alzheimer’s Disease
por: Rosenberry, Terrone L., et al.
Publicado: (2022)

Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42
por: Zaretsky, Dmitry V., et al.
Publicado: (2022)

LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's disease in humans in-vivo
por: Grimmer, Timo, et al.
Publicado: (2014)

Diffusion tensor tractography of the fornix in cerebral amyloid angiopathy, mild cognitive impairment and Alzheimer’s disease
por: Shaikh, Ibrahim, et al.
Publicado: (2022)

Imaging features of small vessel disease in cerebral amyloid angiopathy among patients with Alzheimer’s disease
por: Nagaraja, Nandakumar, et al.
Publicado: (2023)

High Soluble Amyloid-β(42) Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations
por: Sturchio, Andrea, et al.
Publicado: (2022)

Short timescale abnormalities in the states of spontaneous synchrony in the functional neural networks in Alzheimer's disease
por: Sitnikova, Tatiana A., et al.
Publicado: (2018)

Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
Publicado: (2018)

Metabolic changes may precede proteostatic dysfunction in a Drosophila model of amyloid beta peptide toxicity
por: Ott, Stanislav, et al.
Publicado: (2016)

Comparison of the amyloid pore forming properties of rat and human Alzheimer’s beta-amyloid peptide 1-42: Calcium imaging data
por: Di Scala, Coralie, et al.
Publicado: (2016)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

Formation of the 42-mer Amyloid β Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer's Disease
por: Murakami, Kazuma, et al.
Publicado: (2011)

Aβ(1–42) Fibril Structure Illuminates Self-recognition and Replication of Amyloid in Alzheimer’s
por: Xiao, Yiling, et al.
Publicado: (2015)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease
por: Hillen, Heinz
Publicado: (2019)

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
por: Carlson, Christopher, et al.
Publicado: (2016)

Alteration in amyloid β42, phosphorylated tau protein, interleukin 6, and acetylcholine during diabetes-accelerated memory dysfunction in diabetic rats: correlation of amyloid β42 with changes in glucose metabolism
por: Zhou, You, et al.
Publicado: (2015)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease
por: Van der Auwera, Ingrid, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_5i73igc0hpc95tl116bpjpbi6l